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Abstract
Background—Little is known about the medical care resources devoted to diagnosing and 
treating cancer-related symptoms prior to a definitive cancer diagnosis. Previous research using 
SEER-Medicare data to measure incremental costs and utilization associated with cancer started 
with the date of diagnosis. We hypothesized that health care use increases prior to diagnosis of a 
new primary cancer.
Methods—We used a longitudinal case-control design to estimate incremental medical care 
utilization rates. Cases were 121,293 persons enrolled between January, 2000 and December, 2008 
with one or more primary cancers. We selected 522,839 controls randomly from among all health 
plan members who had no tumor registry evidence of cancer prior to January, 2009, and we 
frequency matched controls to cancer cases on a five-to-one ratio by age group, gender, and 
having health plan eligibility in the year of diagnosis of the index cancer case. Utilization data 
were extracted for all cases and controls for the period 2000-2008 from standardized distributed 
data warehouses. To determine when and the extent to which patterns of medical care use change 
preceding a cancer diagnosis, we compute hospitalization rates, hospital days, emergency 
department visits, same-day surgical procedures, ambulatory medical office visits, imaging 
procedures, laboratory tests, and ambulatory prescription dispensings per 1,000 persons per month 
within integrated delivery systems.
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Results—One- to three-fold increases in monthly utilization rates were observed during the three 
to five months prior to a cancer diagnosis, compared to matched non-cancer control groups. This 
pattern was consistent for both aged and non-aged cancer patients. Aged cancer patients had 
higher utilization rates than non-aged cancer patients throughout the year prior to a cancer 
diagnosis.
Conclusion—The pre-diagnosis phase is a resource-intensive component of cancer care 
episodes and should be included in cost of cancer estimates. More research is needed to determine 
whether reliable prognostic markers can be identified as the start of a cancer episode prior to a 
pathology-based diagnosis.
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INTRODUCTION
While many cancers are detected early through screening or as a byproduct of an unrelated 
medical or surgical procedure, significant numbers of cases are diagnosed as a result of a 
search for an underlying cause. Little is known, however, about the medical care resources 
devoted to diagnosing and treating cancer-related symptoms prior to a definitive cancer 
diagnosis. Previous research using SEER-Medicare data to measure incremental costs and 
utilization associated with cancer started with the date of diagnosis.(1-4) We hypothesized 
that health care use increases prior to diagnosis of a new primary cancer for these reasons: 1) 
Signs and symptoms may motivate patients to seek symptom alleviation and diagnosis of the 
underlying disease, which ultimately is discovered to be cancer or, alternatively, an indolent 
tumor is diagnosed because the physician was searching for something else; 2) Misdiagnosis 
that leads to a diagnostic work-up, selection of an incorrect diagnosis, a treatment attempt, 
treatment failure, re-diagnosis, and so on, until the cancer is found; 3) Patients seek 
alleviation of symptoms, but do not elect to pursue the path of confirming a cancer 
diagnosis, leading to a delayed diagnosis; 4) The primary focus of diagnosis and treatment 
may mask a cancer and delay diagnosis; 5) Delay in assigning a cancer diagnosis due to 
existential factors of everyday life may cause delays of weeks or months while the 
diagnostic evidence is accrued; and, 6) Older patients are more likely to have multiple 
chronic diseases that may mask cancer symptoms, leading to a longer and more service-
intensive pattern of utilization leading up to their cancer diagnoses.
To test these hypotheses, we accessed the informatics resources of the Cancer Research 
Network (CRN), a consortium of group-model HMOs with comprehensive administrative 
and electronic medical record information for the populations they serve. The CRN 
represents a highly suitable laboratory for this research as a result of the defined, stable 
populations of cancer patients. This study uses a case-control design and data from four 
CRN health plans over a nine-year period (2000-2008). We used these data to estimate the 
incremental medical care use among adult cancer patients, relative to cancer-free persons, 
aged 18 and older, for the pre-diagnosis phase of care. We define this period as the 12 
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months prior to the month of cancer diagnosis. Measures of utilization included inpatient 
stays and days of care, ambulatory doctor office visits, emergency department visits, same-
day surgical procedures, medication dispensings, imaging procedures, and laboratory tests.
METHODS
Research Setting
This research was conducted within four non-profit integrated health care systems that are 
members of the CRN: Group Health Cooperative (based in Seattle, WA); the Henry Ford 
Health System (based in Detroit, MI); and the Northwest (based in Portland, OR) and 
Colorado regions of Kaiser Permanente (based in Denver, CO). Each of these systems 
provides comprehensive health care to defined populations through closed-panel delivery 
models with salaried physicians. These systems also have tumor registries and integrated 
electronic medical record systems. Each organization provides private and public health 
insurance coverage, including Medicare Advantage and Medicaid risk contracts, resulting in 
diverse enrollments that generally represent their local communities.(5, 6) The Institutional 
Review Boards of the four participating organizations approved this project.
Research Design and Study Population
We employed a longitudinal case-control design to calculate the incremental medical care 
resource used to diagnose cancer. We defined cases as those patients enrolled in one of the 
four participating health plans between January 1, 2000 and December 31, 2008 with 
evidence of one or more primary tumors. These patients had at least 30 days of continuous 
health plan eligibility during this nine-year period. We excluded utilization data on 
individuals whose cancers were diagnosed prior to their 18th birthdays, but included their 
data from their 18th birthdays onward. We randomly selected control patients from health 
plan members with no evidence of cancer prior to January 1, 2009. Controls were frequency 
matched on a five-to-one ratio to cases by age group, gender, and health plan eligibility. 
Pseudo-diagnosis dates were assigned to controls as the date of cancer diagnosis from their 
matched case. We defined four subgroups for the current analyses: cancer patients aged 65 
years and older at time of cancer diagnosis; cancer patients aged less than 65 years at time of 
diagnosis; control patients aged 65 years and older as of the date of diagnosis for the 
matching cancer case; and control patients aged less than 65 years as of the date of diagnosis 
for the matching cancer case. Enrollment gaps of 95 days or less were presumed to be 
unintended administrative changes and were not considered when calculating continuous 
enrollment.
Data
Data on cancer diagnoses, including diagnosis date, were extracted from accredited tumor 
registries for January 1, 2000 through December 31, 2008. Data on health-plan eligibility 
were extracted from enrollment files. We extracted comprehensive utilization data for all 
study cases and controls for 2000-2008 from electronic data warehouses maintained by the 
participating organizations. These data warehouses compile information from EMRs, 
hospital discharge abstracts, claims, hospital, emergency room, same day surgical, and 
medical office ambulatory care encounters, and outpatient dispensings. All persons included 
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in the samples had coverage of ambulatory prescription medications, including Medicare 
Advantage enrollees. We extracted race and ethnicity for cancer patients from tumor 
registries. For controls, this information was extracted from health plan enrollment files and 
hospital discharge abstracts. Data were standardized across plans according to specifications 
established by the CRN's Virtual Data Warehouse.(7)
Measures
We computed eight different monthly utilization rates: short-term hospital admissions, total 
inpatient days, emergency department encounters, same-day surgical procedures, 
ambulatory medical office encounters, outpatient imaging procedures, outpatient laboratory 
procedures, and outpatient medication dispensings. Hospital admissions and days were 
counted as of the date of admission, including stays over 31 days. Medication dispensings, 
including refills, were counted as of the fill date (regardless of the number of days supplied). 
We counted all other care receipt on the day it occurred.
Analysis
The month of cancer diagnosis was set as the index point for cases. We assigned a pseudo 
date to controls to allow us to track utilization rates over the months before and after the 
cancer diagnosis. In this analysis, we present data for the 12 months prior to the month of 
diagnosis recorded in tumor registries. The numbers of cases and controls varied somewhat 
across the months of the pre-diagnosis phase because of differences among patients in health 
plan eligibility relative to the timing of diagnosis.
To determine the statistical significance of the observed differences, we computed Chi-
square tests on categorical variables and t-tests on the differences of means for monthly 
utilization rates between cancer cases and matched controls, and between aged and non-aged 
patients. We conducted analyses for the entire population of cases and controls.
RESULTS
We identified 121,293 cancer cases and 522,839 controls (Table 1). The average age of 
cancer patients was about 60.7 years, compared to 58.5 years for controls. Twenty-one 
percent (N = 24,966) of cancer patients were aged 75 years and older, compared to 17% of 
controls (N = 91,370).. The gender distributions between cancer cases and controls were 
similar: 57% (N = 69,106) of cancer patients were female, compared to 61% (N = 319,997) 
for controls. The differences in race/ethnicity distributions were a function of different data 
sources for each group—tumor registry versus health plan enrollment files. About 69% (N 
=76,527) of cancer cases were incident during the study period. The remaining 44,766 cases 
were prevalent at the beginning of the study period. Breast cancers accounted for 20% of the 
cases (N = 24,684), followed by prostate cancers (14% of cases, N = 16,648) and other 
female genital cancers at (12% of cases, N =14,619). Colorectal cancers accounted for 9% of 
the cases (N= 10,409), and lung cancers represented 8% of cases (N = 9,229).
Hospital discharge rates prior to diagnosis for aged and non-aged cases were at the same 
levels as their respective controls at the beginning of the observation period—14 discharges 
per 1,000 members for aged patients and about 8 discharges per 1,000 members for non-
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aged patients (Figure 1a). During the fourth month prior to cancer diagnosis, however, 
discharge rates for aged cases increased dramatically when compared to aged controls (41 
discharges per 1,000). This rate was two-fold higher than aged controls for the month prior 
to diagnosis. Discharge rates for non-aged cases rose sharply during the last three months of 
the observation period when compared to aged cases (20 discharges per 1,000 members), 
while rates for controls were unchanged across the year. Discharge rates for aged cases and 
controls were consistently higher than non-aged cases and controls, respectively. Rates of 
hospital days used per month and discharges followed similar patterns over the year (Figure 
1b). During the month prior to diagnosis, aged cancer patients used 200 hospital days per 
1,000 members (compared to 85/1,000 for aged controls) and non-aged cancer patients used 
105 days per 1,000 (compared to 30/1,000 for non-aged controls).
For aged cancer patients, emergency department visit rates for aged cancer patients were 78 
visits per 1,000 members for the month before cancer diagnosis, compared to 38 visits per 
1,000 members for aged controls, and 63 per 1,000 members vs. 24 per 1,000 members for 
non-aged cases and controls, respectively (Figure 1c). Same-day surgical procedure rates 
increased significantly during the three months prior to diagnosis for both aged and non-
aged cancer cases, with rates for aged patients remaining consistently higher than non-aged 
patients (Figure 2a). Use of same-day surgical procedures by controls remained relatively 
constant throughout the year. Rates of medical office visits (Figure 2b), imaging procedures 
(Figure 2c), laboratory tests (Figure 3a), and prescription dispensing (Figure 3b) all climbed 
sharply for cases four to 12 months prior to diagnosis, compared to controls, and aged 
patients had consistently higher utilization rates than non-aged patients. (To view larger 
color versions of the above figures, see Supplemental Digital Content 1 (Figure 1a), 
Supplemental Digital Content 2 (Figure 1b), Supplemental Digital Content 3 (Figure 1c), 
Supplemental Digital Content 4 (Figure 2a), Supplemental Digital Content 5 (Figure 2b), 
Supplemental Digital Content 6 (Figure 2c), Supplemental Digital Content 7 (figure 3a), and 
Supplemental Digital Content 8 (figure 3b).)
All utilization differences for both aged and non-aged cases vs. controls were statistically 
significant for at least the two months prior to cancer diagnosis. Twelve of 16 differences 
were statistically significant during the third month prior to diagnosis. For ambulatory office 
visits, laboratory tests, and dispensings, cancer cases have significantly higher utilization 
rates than controls over the entire year prior to diagnosis. The differences in monthly mean 
utilization rates per 1,000 persons by service type and age group for the pre-diagnosis phase 
and their statistical significances are shown in Table 2.)
CONCLUSIONS AND FUTURE RESEARCH
This study confirmed our hypothesis that care utilization increases before a patient is 
diagnosed with cancer. We found that patients had multi-fold increases in use of inpatient, 
ambulatory, emergency department, imaging, laboratory, and pharmacy services during the 
months leading up to a cancer diagnosis, compared to a matched non-cancer control group, 
and this held true for both aged and non-aged cancer patients. These findings indicate that 
all cancer-related care does not start from the diagnosis date, and both cancer research and 
care should account for this fact.
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In addition to confirming the surge in care use before diagnosis, this study also highlights 
areas in need of future research to further articulate this phenomenon. This research should 
address questions, such as:
• What accounts for this ramp-up in utilization rates prior to diagnosis?
• Why do patients age 65 years and older have such markedly higher utilization rates 
compared to patients under age 65?
• What portion of this utilization is the result of delayed recognition of cancer?
• What portion of this utilization is the result of rigorous accrual criteria for new 
primary tumors for cancer registries?
• How much of this utilization is the result of patient and/or provider resistance to 
rapid diagnostic work-ups?
Answering these questions will help shape future research in this area and will illuminate 
our understanding of this important, yet understudied, phase of cancer care. In addition to 
issues of cost and utilization, the search for a cancer diagnosis is a complex, difficult, and 
frustrating experience for patients. As such, more research should examine whether this 
research could help shorten this period.
This Brief Report presents a preliminary view of a four-site, nine-year comprehensive 
database on cancer patients and frequency-matched controls. Future publications from this 
research team will address how medical care costs of cancer differ between HMOs and 
Medicare indemnity coverage, as well as whether cancers occurring before age 65 have 
continued costs effects after age 65.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Cancer cases had accelerating use of eight classes of medical care utilization during the 
year prior to cancer diagnosis compared to a matched non-cancer control group.
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Hospital Discharges per 1,000 Members by Month of Pre-Diagnosis Phase, by Age Group 
and Cancer Status, 2000-2008–All Cancers
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Hospital Days per 1,000 Members by Month of Pre-Diagnosis Phase, by Age Group and 
Cancer Status, 2000-2008–All Cancers
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Same-Day Surgery Procedures per 1,000 Members by Month of Pre-Diagnosis Phase, by 
Age Group and Cancer Status, 2000-2008–All Cancers
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Emergency Room Visits per 1,000 Members by Month of Pre-Diagnosis Phase, by Age 
Group and Cancer Status, 2000-2008–All Cancers
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Ambulatory Medical Office Visits per 1,000 Members by Month of Pre-Diagnosis Phase, by 
Age Group and Cancer Status, 2000-2008–All Cancers
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Ambulatory Imaging Procedures per 1,000 Members by Month of Pre-Diagnosis Phase, by 
Age Group and Cancer Status, 2000-2008–All Cancers
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Ambulatory Laboratory Procedures per 1,000 Members by Month of Pre-Diagnosis Phase, 
by Age Group and Cancer Status, 2000-2008–All Cancers
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Ambulatory Prescription Dispensings per 1,000 Members by Month of Pre-Diagnosis Phase, 
by Age Group and Cancer Status, 2000-2008–All Cancers
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Table 1
Descriptive Statistics for Cancer Cases and Non-Cancer Controls
Variable Cases (n = 121,293) Controls (n = 522,839)
Age at diagnosis
    Mean age (years) ± Std. Dev. 60.7 ± 16.0 58.5 ± 16.3
Age group (%)
    <55 years 38,769 (32) 200,054 (38)
    55-64 27,987 (23) 125,699 (24)
    65-74 29,571 (24) 105,266 (20)
    75+ 24,966 (21) 91,370 (17)
Race/ethnicity (%)
    White 100,764 (83) 238,189 (46)
    Black 7,764 (6) 26,209 (5)
    Asian 3,044 (3) 9,936 (2)
    Hispanic 3,974 (3) 10,906 (2)
    Other race 1,734 (1) 6,399 (1)
    Unknown race 4,013 (3) 231,200 (44)
Year of Cancer Diagnosis (%)
    Prior to 2000 44,766 (37) NA
    2000 8,613 (7) NA
    2001 8,801 (7) NA
    2002 8,800 (7) NA
    2003 8,580 (7) NA
    2004 8,453 (7) NA
    2005 8,216 (7) NA
    2006 8,355 (7) NA
    2007 8,702 (7) NA
    2008 8,007 (8) NA
Cancer Site (%)
    Breast 24,684 (20) NA
    Prostate 16,648 (14) NA
    Other female genitals 14,619 (12) NA
    Skin 10,734 (9) NA
    Colorectal 10,409 (9) NA
    Lung 9,229 (8) NA
    Urinary 7,543 (6) NA
    Digestive 5,744 (5) NA
    Hematopoietic, Reticuloendothelial 5,242 (4) NA
    Lymph Nodes 3,462 (3) NA
    All other cancers (10) NA
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Variable Cases (n = 121,293) Controls (n = 522,839)
Gender (%)
    Male 52,187 (43) 202,842 (39)
    Female 69,106 (57) 319,997 (61)
Length of Enrollment Categories
    < 13 months 8,525 (7) 54,383 (10)
    13-24 months 9,023 (7) 45,709 (9)
    25-36 months 9,081 (7) 41,971 (8)
    37-48 months 9,114 (8) 39,307 (8)
    49-60 months 8,609 (7) 35,441 (7)
    61-72 months 8,132 (7) 31,644 (6)
    73-84 months 8,350 (7) 32,767 (6)
    85-96 months 8,420 (7) 34,772 (7)
    97-108 months 52,039 (43) 206,845 (40)
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